New york: Helus Pharma, formerly known as Cybin Inc, marked a significant transition toward commercialisation as it began trading on the Nasdaq Global Market and Cboe Canada under the ticker symbol HELP. This move reflects a strategic rebrand and corporate repositioning aimed at advancing its role in the pharmaceutical industry.

According to BERNAMA News Agency, the clinical-stage pharmaceutical company stated that the Helus Pharma identity builds on the foundation laid by Cybin. This rebrand underscores its evolution into a commercial-ready drug developer with a focus on novel serotonergic agonists (NSAs) intended to redefine mental health care.

Eric So, the interim chief executive officer, noted that the rebrand signifies the company's readiness to transition from discovery and development to market delivery. This readiness is supported by a robust intellectual property portfolio that includes over 350 filed patents.

Key clinical milestones anticipated in 2026 are expected to position Helus Pharma to introduce differentiated therapies, enhance patient outcomes, and generate long-term value for healthcare stakeholders and shareholders. The company's shares now trade on Nasdaq following a transfer from the NYSE American, while it maintains its Cboe Canada listing under the same ticker. Helus Pharma plans to seek shareholder approval to formally change its legal name at its next annual and special meeting.

Helus Pharma's lead programme, HLP003, is currently in Phase 3 development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the United States Food and Drug Administration. Preparations for commercialisation are underway, pending regulatory approvals.

Additionally, the company is advancing HLP004, an NSA in a Phase 2 study for generalised anxiety disorder, with topline data expected in the first quarter of 2026.